{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:56:50Z","timestamp":1791633410834,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.vhri.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T19:31:10Z","timestamp":1558035070000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective"],"prefix":"10.1016","volume":"20","author":[{"given":"Eleonora","family":"Aiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Manuel","family":"Bianculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devarshi","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Gunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2019.03.002_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheumatic Dis"},{"issue":"9","key":"10.1016\/j.vhri.2019.03.002_bib3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3899\/jrheum.091315","article-title":"Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health","volume":"37","author":"Taylor","year":"2010","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.vhri.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","article-title":"Psoriatic arthritis: epidemiology, diagnosis, and treatment","volume":"5","author":"Liu","year":"2014","journal-title":"World J Orthop"},{"issue":"4","key":"10.1016\/j.vhri.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.vhri.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/2040622315582354","article-title":"Psoriatic arthritis: latest treatments and their place in therapy","volume":"6","author":"Kang","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"issue":"12","key":"10.1016\/j.vhri.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.vhri.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/rheumatology\/keq369","article-title":"Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study","volume":"50","author":"Soriano","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.vhri.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-013-2412-2","article-title":"Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria","volume":"33","author":"Hern\u00e1n","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.vhri.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5114\/reum.2017.68911","article-title":"Fatigue \u2013 an underestimated symptom in psoriatic arthritis","volume":"55","author":"Krajewska-W\u0142odarczyk","year":"2017","journal-title":"Reumatologia"},{"issue":"suppl 3","key":"10.1016\/j.vhri.2019.03.002_bib11","doi-asserted-by":"crossref","first-page":"A681","DOI":"10.1136\/annrheumdis-2013-eular.2014","article-title":"SAT0289Impact of psoriatic arthritis (PSA) on health care utilization (HCU) and quality of life (Qol)","volume":"72","author":"Khraishi","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.vhri.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.121500","article-title":"Incremental effects of\u00a0comorbidity on quality of life in patients with psoriatic arthritis","volume":"40","author":"Husted","year":"2013","journal-title":"J Rheumatol"},{"issue":"5 suppl 51","key":"10.1016\/j.vhri.2019.03.002_bib13","first-page":"S62","article-title":"Mortality in psoriatic arthritis","volume":"26","author":"Gladman","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/annrheumdis-2017-eular.3569","article-title":"FRI0483 Work capacity and quality of life in a cohort of patients with early psoriatic arthritis in argentina","volume":"76","author":"Colombres","year":"2017","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"10.1016\/j.vhri.2019.03.002_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheumatic Dis"},{"issue":"3","key":"10.1016\/j.vhri.2019.03.002_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheumatic Dis"},{"issue":"5","key":"10.1016\/j.vhri.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.vhri.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheumatic Dis"},{"issue":"1","key":"10.1016\/j.vhri.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of\u00a0psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.vhri.2019.03.002_bib20","article-title":"Treatment patterns in psoriatic arthritis: experience from a real-world setting","author":"Brom","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5 suppl 93","key":"10.1016\/j.vhri.2019.03.002_bib21","first-page":"S119","article-title":"Interleukin-17 inhibition in psoriatic arthritis","volume":"33","author":"Boyd","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vhri.2019.03.002_bib22","series-title":"Food and Medical Technology, Argentina. Secukinumab for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis","year":"2016"},{"issue":"14","key":"10.1016\/j.vhri.2019.03.002_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2019.03.002_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vhri.2019.03.002_bib25","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis through 3 years: efficacy and safety results from a phase 3 trial","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vhri.2019.03.002_bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.vhri.2019.03.002_bib27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2019.03.002_bib28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2017-eular.1260","article-title":"SAT0470Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.vhri.2019.03.002_bib29","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, McInnes IB, Mease PJ, et\u00a0al. Secukinumab provides sustained improvement in signs and symptoms of patients with active psoriatic arthritis up to 3 years: Data from FUTURE 1 and FUTURE 2 studies. Presented at: 26th European Academy of Dermatology and Venereology Congress; September 13-17, 2017; Geneva, Switzerland.","DOI":"10.1093\/rheumatology\/kex062.072"},{"key":"10.1016\/j.vhri.2019.03.002_bib30","article-title":"Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5 year efficacy and safety results from a phase 3 trial","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.vhri.2019.03.002_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using\u00a0a\u00a0matching-adjusted indirect comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.vhri.2019.03.002_bib32","first-page":"193","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness results versus etanercept up to 24 weeks using a matching-adjusted indirect comparison","volume":"19","author":"Nash","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.vhri.2019.03.002_bib33","author":"Strand"},{"key":"10.1016\/j.vhri.2019.03.002_bib35","doi-asserted-by":"crossref","first-page":"A233","DOI":"10.1016\/j.jval.2016.03.1151","article-title":"A new cost-effectiveness framework for modeling psoriatic arthritis treatments","volume":"19","author":"Graham","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2019.03.002_bib37","first-page":"1","article-title":"Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective","volume":"21","author":"Goeree","year":"2017","journal-title":"J Med Econ"},{"issue":"10","key":"10.1016\/j.vhri.2019.03.002_bib38","doi-asserted-by":"crossref","first-page":"i","DOI":"10.3310\/hta15100","article-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","volume":"15","author":"Rodgers","year":"2011","journal-title":"Health Technol Assess"},{"issue":"31","key":"10.1016\/j.vhri.2019.03.002_bib39","doi-asserted-by":"crossref","DOI":"10.3310\/hta10310","article-title":"Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2019.03.002_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"10.1016\/j.vhri.2019.03.002_bib41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10198-011-0335-x","article-title":"Cost effectiveness of golimumab for the treatment of active psoriatic arthritis","volume":"13","author":"Cummins","year":"2012","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.vhri.2019.03.002_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jval.2010.10.016","article-title":"Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis","volume":"14","author":"Cummins","year":"2011","journal-title":"Value Health"},{"issue":"suppl 4","key":"10.1016\/j.vhri.2019.03.002_bib43","doi-asserted-by":"crossref","first-page":"iv39","DOI":"10.1093\/rheumatology\/ker245","article-title":"Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis","volume":"50","author":"Bojke","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.vhri.2019.03.002_bib44","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.vhri.2019.03.002_bib45","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3899\/jrheum.100069","article-title":"Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study","volume":"37","author":"Gladman","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vhri.2019.03.002_bib48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/keg107","article-title":"The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study","volume":"42","author":"Kobelt","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.vhri.2019.03.002_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1365-2133.2002.04920.x","article-title":"Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment","volume":"147","author":"Hartman","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.vhri.2019.03.002_bib50","author":"Lesley"},{"key":"10.1016\/j.vhri.2019.03.002_bib53","first-page":"1","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess"},{"issue":"11","key":"10.1016\/j.vhri.2019.03.002_bib54","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/rheumatology\/kem221","article-title":"The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis","volume":"46","author":"Bravo Vergel","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vhri.2019.03.002_bib55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr.20104","article-title":"Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies","volume":"62","author":"Saad","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.vhri.2019.03.002_bib56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/ard.2008.103473","article-title":"Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden","volume":"69","author":"Gulfe","year":"2010","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.vhri.2019.03.002_bib57","doi-asserted-by":"crossref","first-page":"e000723","DOI":"10.1136\/rmdopen-2018-000723","article-title":"Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"issue":"suppl 10","key":"10.1016\/j.vhri.2019.03.002_bib58","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial","volume":"68","author":"McInnes","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109919300482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109919300482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:10:28Z","timestamp":1761941428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109919300482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":52,"alternative-id":["S2212109919300482"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2019.03.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}